Director Physician, Department of Hematology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Specializes in individualized treatment of leukemia, myeloma, and lymphoma, as well as precise diagnosis and treatment of various types of blood cell abnormalities. Responsible for the transplant subspecialty group of the department. Has long been engaged in clinical, scientific research, and teaching work in hematologic malignancies. Main research directions include drug resistance mechanisms and individualized diagnosis and treatment of hematologic malignancies, with emphasis on the value and application of oncogenes such as Notch1 and EVI-1 in the diagnosis and treatment of leukemia, the application of anti-angiogenic therapy in malignant hematologic diseases, and the application of transgenic zebrafish models in basic research on hematologic malignancies. Has successfully established multiple transgenic leukemia zebrafish lines, which have been certified and included by the international zebrafish official website. Has successively undertaken multiple projects including the National Natural Science Foundation for Young Scholars, municipal science and technology commission, university-level, and hospital-level projects. Has published more than 30 academic papers in domestic and international academic journals, and has participated in international academic conferences with more than 10 exchanged papers. From May 2014 to April 2015, was a senior visiting scholar at the Fox Chase Cancer Center and Stem Cell Transplant Center of Temple University in the United States. In October 2015, visited the University of Ottawa Faculty of Medicine in Canada. In August 2018, went to Los Angeles to participate in the "Asian Master Class" of the International Myeloma Foundation. Currently mainly responsible for the work of the hematopoietic stem cell transplantation subspecialty and the leukemia clinical treatment group of the department. Based on the number of sterile ward beds, the annual number and quality of transplants completed have reached the leading level nationwide, especially the experience in allogeneic transplantation diagnosis and treatment of multiple myeloma, which is at the leading domestic level. Able to formulate precise combinations and sequential regimens of immune-targeted therapy combined with traditional cytotoxic drugs according to the pathogenic gene profiles and individual tolerance of patients with different tumor types. Also has relatively rich clinical experience in the use of new technologies such as CAR-T and new drugs such as ADC drugs and dual-target monoclonal antibodies.